Digestive Diseases
| Crohn's Disease
Digestive Diseases
Crohn's Disease
Effect of risankizumab treatment on extraintestinal manifestations (EIMS) in patients with moderate to severe Crohn’s disease (CD): results from the ADVANCE, MOTIVATE and FORTIFY STUDIES
book_2
Source:
UEG Week 2023 - Oral session
calendar_today
Published on Medfyle:
November 2023
import_contacts
5
min
In this medfyle
Extraintestinal manifestations of IBD are associated with poor quality of life and greater disability. Analysis of pooled data from the ADVANCE and MOTIVATE induction and FORTIFY maintenance studies evaluated EIM resolution in patients with moderate to severe Crohn’s disease who received risankizumab versus placebo. Induction and maintenance treatment with risankizumab led to sustained resolution of EIMs.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
